Human medicines European public assessment report (EPAR): Tizveni, tislelizumab, Status: Opinion
Overview On 22 February 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Tizveni, intended for the treatment of locally advanced or …